Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

1733 - Competing nomogram for late-period breast cancer-specific death in patients with early-stage hormone receptor-positive breast cancer


29 Sep 2019


Poster Display session 2


Tumour Site

Breast Cancer


Jianfei Fu


Annals of Oncology (2019) 30 (suppl_5): v55-v98. 10.1093/annonc/mdz240


J. Fu1, D. Li2, L. Wu3, K. Yu1, J. Du1

Author affiliations

  • 1 Department Of Oncology, Central Hospital of Jinhua, 321000 - Jinhua/CN
  • 2 Department Of Medical Oncology, Second Affiliated Hospital of Zhejiang University School of Medicine, 310009 - Hangzhou/CN
  • 3 Department Of Gastroenterology, Second Affiliated Hospital of Zhejiang University School of Medicine, 310009 - Hangzhou/CN


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1733


More than half of early breast cancer recurrences occur after 5 years from the initial diagnosis. An individualized estimate of the risk of late-period breast cancer-specific death (LP-BCSD) after 5 years of endocrine therapy (ET) can improve decision-making for extended endocrine therapy (EET).


A total of 147,059 eligible patients with breast cancer who survived 5+ years after diagnosis between 1990 and 2007 were identified from the Surveillance, Epidemiology, and End Results (SEER) database. Univariate and multivariate analyses based on the competing risk regression model were used to evaluate predictive factors for high risk of LP-BCSD or LP-non-BCSD. Significant factors were used to build a nomogram to individualize estimates of LP-BCSD or LP-non-BCSD.


The 5- and 10-year LP-BCSD rates were 5.67% and 10.06%, respectively, and the 5- and 10-year LP-non-BCSD rates were 6.72% and 15.50%, respectively. Young age, black race, single marital status, poor differentiation, large tumor size, lymph node metastasis, and ER+/PR- status were independent predictive factors for high risk of LP-BCSD. Age was the most important factor for predicting high risk of LP-non-BCSD. The nomograms, which were based on significant factors identified by the competing risk regression model. A risk score system based on the competing risk nomogram was established to describe the relative risk of LP-BCSD and LP-non-BCSD.


This study explored the novel endpoint of LP-BCSD for further clinical trials. The risk score system is highly useful for patient counseling, especially in discussing EET options with elderly or comorbid patients.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Jianfei Fu.


Science & Technology Division of Jinhua Zhejiang Province.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.